Education
About Us
Working with TipRanks
Follow Us
Mainz Biomed B.V. (MYNZ)
NASDAQ:MYNZ
MYNZ Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.65 - $43.24
Previous CloseN/A
Volume20.13K
Average Volume (3M)162.17K
Market Cap
$10.12M
Enterprise ValueN/A
Total Cash (Recent Filing)$122.57K
Total Debt (Recent Filing)$2.98M
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Apr 15, 2025EPS Estimate
-3.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-65.57
Shares Outstanding3,038,853
10 Day Avg. Volume139,268
30 Day Avg. Volume162,167
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)42.65
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$14.00Price Target Upside334.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Mainz Biomed B.V. News
PremiumCompany Announcements
Mainz Biomed Reports 2024 Financial Success and Strategic Advances
PremiumCompany Announcements
Mainz Biomed’s Breakthrough in Pancreatic Cancer Detection
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsMainz Biomed announced the enrollment of the first subject into the eAArly DETECT 2 clinical study in the US.
PartnershipsAn agreement with Quest Diagnostics has been signed for the ReconAAsense study with an option for commercialization.
Bears Say
Capital RequirementsThe company needs to raise a significant amount of capital to complete the eAArly DETECT 2 and a pivotal study before regulatory submission.
Financial PerformanceNet loss totaled $11.0M in the first half of the year, with revenue being only $0.5M, indicating financial challenges.
---
Ownership Overview
―
Insiders
0.41%
Mutual Funds
10.84% Other Institutional Investors
88.75% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
MYNZ FAQ
What was Mainz Biomed B.V.’s price range in the past 12 months?
Mainz Biomed B.V. lowest stock price was $2.65 and its highest was $43.24 in the past 12 months.
What is Mainz Biomed B.V.’s market cap?
Mainz Biomed B.V.’s market cap is $10.12M.
When is Mainz Biomed B.V.’s upcoming earnings report date?
Mainz Biomed B.V.’s upcoming earnings report date is Apr 15, 2025 which is in 3 days.
How were Mainz Biomed B.V.’s earnings last quarter?
Mainz Biomed B.V. released its earnings results on Apr 01, 2025. The company reported -$3.01 earnings per share for the quarter, beating the consensus estimate of -$3.6 by $0.59.
Is Mainz Biomed B.V. overvalued?
According to Wall Street analysts Mainz Biomed B.V.’s price is currently Undervalued.
Does Mainz Biomed B.V. pay dividends?
Mainz Biomed B.V. does not currently pay dividends.
What is Mainz Biomed B.V.’s EPS estimate?
Mainz Biomed B.V.’s EPS estimate is -3.01.
How many shares outstanding does Mainz Biomed B.V. have?
Mainz Biomed B.V. has 3,038,853 shares outstanding.
What happened to Mainz Biomed B.V.’s price movement after its last earnings report?
Mainz Biomed B.V. reported an EPS of -$3.01 in its last earnings report, beating expectations of -$3.6. Following the earnings report the stock price went down -8.723%.
Which hedge fund is a major shareholder of Mainz Biomed B.V.?
Currently, no hedge funds are holding shares in MYNZ
---
Company Description
Mainz Biomed B.V.
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
---
MYNZ Stock 12 Month Forecast
Average Price Target
$14.00
▲(334.78% Upside)
Technical Analysis
Best Analysts Covering MYNZ
1 Year
1 Year Success Rate
0/8 ratings generated profit
1 Year Average Return
-86.51%
reiterated a buy rating 10 months ago
Copying Justin Walsh's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -86.51% per trade.
---